CA2239360A1 - G-csf analog compositions and methods - Google Patents
G-csf analog compositions and methodsInfo
- Publication number
- CA2239360A1 CA2239360A1 CA002239360A CA2239360A CA2239360A1 CA 2239360 A1 CA2239360 A1 CA 2239360A1 CA 002239360 A CA002239360 A CA 002239360A CA 2239360 A CA2239360 A CA 2239360A CA 2239360 A1 CA2239360 A1 CA 2239360A1
- Authority
- CA
- Canada
- Prior art keywords
- analogs
- csf
- methods
- another aspect
- compositions
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Abstract
Provided herein are granulocyte colony stimulating factor ("G-CSF") analogs, compositions containing such analogs, and related compositions. In another aspect, provided herein are nucleic acids encoding the present analogs or related nucleic acids, related host cells and vectors. In yet another aspect, provided herein are computer programs and apparatuses for expressing the three dimensional structure of G-CSF and analogs thereof. In another aspect, provided herein are methods for rationally designing G-CSF analogs and related compositions. In yet another aspect, provided herein are methods for treatment using the present G-CSF analogs.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2381489A CA2381489C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/010,099 | 1993-01-28 | ||
US08/010,099 US5581476A (en) | 1993-01-28 | 1993-01-28 | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
CA002153896A CA2153896C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002153896A Division CA2153896C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA2381489A Division CA2381489C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Publications (2)
Publication Number | Publication Date |
---|---|
CA2239360A1 true CA2239360A1 (en) | 1994-08-04 |
CA2239360C CA2239360C (en) | 2002-07-16 |
Family
ID=21743861
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002239360A Expired - Lifetime CA2239360C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
CA002153896A Expired - Lifetime CA2153896C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
CA2381489A Expired - Lifetime CA2381489C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
CA2711007A Expired - Lifetime CA2711007C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002153896A Expired - Lifetime CA2153896C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
CA2381489A Expired - Lifetime CA2381489C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
CA2711007A Expired - Lifetime CA2711007C (en) | 1993-01-28 | 1994-01-25 | G-csf analog compositions and methods |
Country Status (22)
Country | Link |
---|---|
US (6) | US5581476A (en) |
EP (8) | EP0612846B1 (en) |
JP (7) | JPH08506018A (en) |
KR (2) | KR100375274B1 (en) |
CN (3) | CN1118572C (en) |
AT (2) | ATE195552T1 (en) |
AU (2) | AU697451B2 (en) |
CA (4) | CA2239360C (en) |
DE (1) | DE69425516T2 (en) |
DK (3) | DK2345724T3 (en) |
ES (3) | ES2382927T3 (en) |
FI (2) | FI120769B (en) |
GR (1) | GR3034745T3 (en) |
HK (2) | HK1009288A1 (en) |
IL (6) | IL145994A (en) |
LU (1) | LU92265I2 (en) |
LV (1) | LV12642B (en) |
NO (3) | NO952974L (en) |
NZ (5) | NZ314960A (en) |
PT (3) | PT1482046E (en) |
WO (1) | WO1994017185A1 (en) |
ZA (1) | ZA94568B (en) |
Families Citing this family (140)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE68925966T2 (en) * | 1988-12-22 | 1996-08-29 | Kirin Amgen Inc | CHEMICALLY MODIFIED GRANULOCYTE COLONY EXCITING FACTOR |
US20020177688A1 (en) * | 1988-12-22 | 2002-11-28 | Kirin-Amgen, Inc., | Chemically-modified G-CSF |
US5581476A (en) * | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US20030053982A1 (en) * | 1994-09-26 | 2003-03-20 | Kinstler Olaf B. | N-terminally chemically modified protein compositions and methods |
US5824784A (en) * | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
JP3708151B2 (en) * | 1994-12-15 | 2005-10-19 | 協和醗酵工業株式会社 | Quantification of PEGylated human granulocyte colony-stimulating factor |
ATE364629T1 (en) * | 1996-01-22 | 2007-07-15 | Curis Inc | METHODS FOR PRODUCING OP-1 MORPHOGEN ANALOGUES |
US20030185792A1 (en) * | 1996-01-22 | 2003-10-02 | Curis, Inc. | Morphogen analogs of bone morphogenic proteins |
US5835382A (en) * | 1996-04-26 | 1998-11-10 | The Scripps Research Institute | Small molecule mimetics of erythropoietin |
US6128582A (en) | 1996-04-30 | 2000-10-03 | Vertex Pharmaceuticals Incorporated | Molecules comprising an IMPDH-like binding pocket and encoded data storage medium capable of graphically displaying them |
US20080076706A1 (en) * | 1997-07-14 | 2008-03-27 | Bolder Biotechnology, Inc. | Derivatives of Growth Hormone and Related Proteins, and Methods of Use Thereof |
IL133974A0 (en) * | 1997-07-14 | 2001-04-30 | Bolder Biotechnology Inc | Derivatives of growth hormone and related proteins |
US6753165B1 (en) | 1999-01-14 | 2004-06-22 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
US6017876A (en) | 1997-08-15 | 2000-01-25 | Amgen Inc. | Chemical modification of granulocyte-colony stimulating factor (G-CSF) bioactivity |
CN1061992C (en) * | 1997-11-19 | 2001-02-14 | 蒋永平 | Colony stimulating factor for recombination of human granulocytes and medicinal composition thereof |
WO1999055735A1 (en) * | 1998-04-30 | 1999-11-04 | Tanox, Inc. | G-csf receptor agonist antibodies and screening method therefor |
TWI242563B (en) * | 1998-04-30 | 2005-11-01 | Tanox Inc | Monoclonal agonist antibodies which specifically bind to or interact with human G-CSF receptor |
US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
US6979442B1 (en) | 1998-08-17 | 2005-12-27 | Pfizer Inc. | Stabilized protein compositions |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6451346B1 (en) * | 1998-12-23 | 2002-09-17 | Amgen Inc | Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents |
US6245740B1 (en) | 1998-12-23 | 2001-06-12 | Amgen Inc. | Polyol:oil suspensions for the sustained release of proteins |
US7208473B2 (en) * | 1999-01-06 | 2007-04-24 | Xencor, Inc. | Nucleic acids and protein variants of hG-CSF with granulopoietic activity |
CA2357811A1 (en) * | 1999-01-06 | 2000-07-13 | Xencor, Inc. | Nucleic acids and proteins corresponding to mutants of g-csf with granulopoietic activity |
US8288126B2 (en) | 1999-01-14 | 2012-10-16 | Bolder Biotechnology, Inc. | Methods for making proteins containing free cysteine residues |
KR100689212B1 (en) * | 1999-01-29 | 2007-03-09 | 암겐 인코포레이티드 | Gcsf conjugates |
US6500418B1 (en) * | 1999-02-12 | 2002-12-31 | The Washington University | Stimulating neutrophil function to treat inflammatory bowel disease |
JP2000319298A (en) * | 1999-03-04 | 2000-11-21 | Seibutsu Bunshi Kogaku Kenkyusho:Kk | Crystal and structural coordinate of protein complex, and use of structural coordinate |
US7247490B2 (en) | 1999-04-06 | 2007-07-24 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7250305B2 (en) | 2001-07-30 | 2007-07-31 | Uab Research Foundation | Use of dye to distinguish salt and protein crystals under microcrystallization conditions |
ATE357656T1 (en) * | 1999-04-06 | 2007-04-15 | Univ Alabama Res Found | DEVICE FOR SCREENING CRYSTALIZATION CONDITIONS IN CRYSTAL GROWING SOLUTIONS |
US20030022383A1 (en) * | 1999-04-06 | 2003-01-30 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
US7244396B2 (en) | 1999-04-06 | 2007-07-17 | Uab Research Foundation | Method for preparation of microarrays for screening of crystal growth conditions |
US7214540B2 (en) * | 1999-04-06 | 2007-05-08 | Uab Research Foundation | Method for screening crystallization conditions in solution crystal growth |
AU4835200A (en) * | 1999-05-10 | 2000-11-21 | Regents Of The University Of California, The | Methods and compositions for controlled polypeptide synthesis |
US6296673B1 (en) * | 1999-06-18 | 2001-10-02 | The Regents Of The University Of California | Methods and apparatus for performing array microcrystallizations |
US6630006B2 (en) * | 1999-06-18 | 2003-10-07 | The Regents Of The University Of California | Method for screening microcrystallizations for crystal formation |
US7058517B1 (en) | 1999-06-25 | 2006-06-06 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
NZ517184A (en) * | 1999-07-13 | 2004-02-27 | Bolder Biotechnology Inc | Immunoglobulin fusion proteins that are cytokines or growth factors joined to an Immunoglobulin domain |
US8106098B2 (en) * | 1999-08-09 | 2012-01-31 | The General Hospital Corporation | Protein conjugates with a water-soluble biocompatible, biodegradable polymer |
DE60139110D1 (en) * | 2000-01-10 | 2009-08-13 | Maxygen Holdings Ltd | G-CSF CONJUGATES |
US6646110B2 (en) * | 2000-01-10 | 2003-11-11 | Maxygen Holdings Ltd. | G-CSF polypeptides and conjugates |
US6555660B2 (en) * | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
US6831158B2 (en) * | 2000-01-10 | 2004-12-14 | Maxygen Holdings Ltd. | G-CSF conjugates |
GB0008563D0 (en) * | 2000-04-07 | 2000-05-24 | Cambridge Discovery Chemistry | Investigating different physical and/or chemical forms of materials |
DK1043239T3 (en) * | 2000-06-16 | 2004-06-14 | Vsi Holding As | Container with foldable sides |
US6931326B1 (en) | 2000-06-26 | 2005-08-16 | Genaissance Pharmaceuticals, Inc. | Methods for obtaining and using haplotype data |
AU2001286931A1 (en) * | 2000-08-30 | 2002-03-13 | The Salk Institute For Biological Studies | Methods and compositions for determining isomerase enzymatic activity |
US20040254351A1 (en) * | 2000-09-07 | 2004-12-16 | Beals John Michael | Hyperglycosylated polypeptides |
US6946548B2 (en) * | 2000-09-08 | 2005-09-20 | Massachusetts Institute Of Technology | G-CSF analog compositions and methods |
AU2002212108A1 (en) * | 2000-11-02 | 2002-05-15 | Maxygen Aps | Single-chain multimeric polypeptides |
CA2440467A1 (en) * | 2001-03-12 | 2002-09-19 | Board Of Regents, University Of Texas System | Ensemble-based strategy for the design of protein pharmaceuticals |
DE10112825A1 (en) * | 2001-03-16 | 2002-10-02 | Fresenius Kabi De Gmbh | HESylation of active ingredients in aqueous solution |
US7670429B2 (en) | 2001-04-05 | 2010-03-02 | The California Institute Of Technology | High throughput screening of crystallization of materials |
US6998219B2 (en) * | 2001-06-27 | 2006-02-14 | University Of South Florida | Maskless photolithography for etching and deposition |
AU2002325819B2 (en) * | 2001-07-11 | 2008-06-19 | Maxygen, Inc. | G-CSF Conjugates |
US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
US20040247562A1 (en) * | 2001-09-28 | 2004-12-09 | Sang Yup Lee | Diagnostic method for cancer characterized in the detection of the deletion of g-csf exon 3 |
DE10209821A1 (en) * | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of proteins to a modified polysaccharide |
DE10209822A1 (en) | 2002-03-06 | 2003-09-25 | Biotechnologie Ges Mittelhesse | Coupling of low molecular weight substances to a modified polysaccharide |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
WO2003100002A2 (en) * | 2002-05-23 | 2003-12-04 | Board Of Regents, The University Of Texas System | Predicting the significance of single nucleotide polymorphisms (snps) using ensemble-based structural energetics |
US20040007672A1 (en) * | 2002-07-10 | 2004-01-15 | Delucas Lawrence J. | Method for distinguishing between biomolecule and non-biomolecule crystals |
ES2343518T3 (en) * | 2002-09-09 | 2010-08-03 | Hanall Biopharma Co., Ltd. | ALFA INTERFERATED POLYPEPTIDES MODIFIED PROTEASAS RESISTANT. |
WO2004024776A1 (en) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | Method of producing hydroxyalkyl starch derivatives |
DE10242076A1 (en) * | 2002-09-11 | 2004-03-25 | Fresenius Kabi Deutschland Gmbh | New covalently bonded conjugates of hydroxyalkyl starch with allergens, useful as modified allergens with depot effect for use in specific immunotherapy for combating allergies, e.g. hay fever |
US9453251B2 (en) | 2002-10-08 | 2016-09-27 | Pfenex Inc. | Expression of mammalian proteins in Pseudomonas fluorescens |
AU2003273413A1 (en) * | 2002-10-08 | 2004-05-04 | Fresenius Kabi Deutschland Gmbh | Pharmaceutically active oligosaccharide conjugates |
CA2511815A1 (en) * | 2002-12-26 | 2004-07-22 | Mountain View Pharmaceuticals, Inc. | Polymer conjugates of cytokines, chemokines, growth factors, polypeptide hormones and antagonists thereof with preserved receptor-binding activity |
NZ541124A (en) * | 2002-12-26 | 2008-08-29 | Mountain View Pharmaceuticals | Polymer conjugates of interferon-beta with enhanced biological potency |
US7785601B2 (en) | 2002-12-31 | 2010-08-31 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
US7695723B2 (en) | 2002-12-31 | 2010-04-13 | Sygnis Bioscience Gmbh & Co. Kg | Methods of treating neurological conditions with hematopoietic growth factors |
DK1648931T3 (en) | 2003-07-21 | 2011-03-07 | Transgene Sa | Multifunctional cytokines |
EP1653991A2 (en) * | 2003-08-08 | 2006-05-10 | Fresenius Kabi Deutschland GmbH | Conjugates of a polymer and a protein linked by an oxime linking group |
WO2005014655A2 (en) * | 2003-08-08 | 2005-02-17 | Fresenius Kabi Deutschland Gmbh | Conjugates of hydroxyalkyl starch and a protein |
DK2213295T3 (en) * | 2003-10-24 | 2013-05-06 | Nora Therapeutics Inc | Method of Obtaining Data Useful for Identifying a Patient at Risk of Having a Difficulty in Pregnancy |
US20090226397A1 (en) * | 2003-10-24 | 2009-09-10 | Nora Therapeutics, Inc. | Compositions and methods for reducing the likelihood of implantation failure or miscarriage in recipients of artificial insemination |
US8338373B2 (en) * | 2003-10-24 | 2012-12-25 | Nora Therapeutics, Inc. | Method for reducing the risk of spontaneous abortion in a human female subject |
US7220407B2 (en) * | 2003-10-27 | 2007-05-22 | Amgen Inc. | G-CSF therapy as an adjunct to reperfusion therapy in the treatment of acute myocardial infarction |
US20060122784A1 (en) * | 2004-12-03 | 2006-06-08 | Ishikawa Muriel Y | System and method for augmenting a humoral immune response |
CA2552241C (en) | 2003-12-30 | 2013-10-01 | Durect Corporation | Co-polymeric devices for controlled release of active agents |
TWI417303B (en) | 2004-03-11 | 2013-12-01 | Fresenius Kabi De Gmbh | Conjugates of hydroxyalkyl starch and a protein, prepared by reductive amination |
AR048918A1 (en) * | 2004-03-11 | 2006-06-14 | Fresenius Kabi De Gmbh | CONJUGADOS DE ALMIDON DE HIDROXIETILO Y ERITROPOYETINA |
EP2412816B1 (en) | 2004-07-26 | 2014-12-03 | Pfenex Inc. | Process for improved protein expression by strain engineering |
CA2586365A1 (en) * | 2004-11-05 | 2006-05-26 | Northwestern University | Use of scf and g-csf in the treatment of cerebral ischemia and neurological disorders |
US7741096B2 (en) * | 2004-12-10 | 2010-06-22 | Genentech, Inc. | Crystal structure of hepatocyte growth factor activator complexed with Kunitz domain inhibitor |
WO2006067170A1 (en) * | 2004-12-23 | 2006-06-29 | Laboratoires Serono S.A. | G-csf polypeptides and uses thereof |
NZ556436A (en) | 2005-01-10 | 2010-11-26 | Biogenerix Ag | Glycopegylated granulocyte colony stimulating factor |
KR100657749B1 (en) * | 2005-04-13 | 2006-12-20 | 씨제이 주식회사 | Human Granulocyte-Colony Stimulating Factor Isoform and Composition thereof |
BRPI0611221A2 (en) * | 2005-06-01 | 2010-08-24 | Maxygen Holdings Ltd | pegylated g-csf polypeptides and their production methods |
KR100694994B1 (en) * | 2005-06-13 | 2007-03-14 | 씨제이 주식회사 | Human Granulocyte-Colony Stimulating Factor Isoforms |
KR100735784B1 (en) | 2005-07-20 | 2007-07-06 | 재단법인 목암생명공학연구소 | Mutant of granulocyte-colony stimulating factorG-CSF and chemically conjugated polypeptide thereof |
DK1917227T3 (en) * | 2005-08-15 | 2013-05-27 | Phares Drug Delivery Ag | Crystal forms of astaxanthin |
WO2007024940A2 (en) * | 2005-08-22 | 2007-03-01 | Dana-Farber Cancer Institute, Inc. | Mitochondrial localization of muc1 |
US20070112804A1 (en) * | 2005-11-07 | 2007-05-17 | Desimas Bruce E | Systems and methods for generating automated software workflows for biological testing |
GB0605684D0 (en) * | 2006-03-21 | 2006-05-03 | Sicor Biotech Uab | Method For Purifying Granulocyte-Colony Stimulating Factor |
WO2008111996A2 (en) * | 2006-07-20 | 2008-09-18 | Dana-Farber Cancer Institute, Inc. | Muc1-ikb kinase complexes and their activities |
WO2008097844A2 (en) * | 2007-02-02 | 2008-08-14 | Dana -Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of apoptosis by muc1 and bh3- containing proapoptotic proteins |
US7972870B2 (en) | 2007-02-02 | 2011-07-05 | Dana-Farber Cancer Institute, Inc. | Methods and compositions relating to the regulation of MUC1 by HSF1 and STAT3 |
JP4375412B2 (en) * | 2007-02-19 | 2009-12-02 | 株式会社デンソー | Evaporator unit |
US9580719B2 (en) | 2007-04-27 | 2017-02-28 | Pfenex, Inc. | Method for rapidly screening microbial hosts to identify certain strains with improved yield and/or quality in the expression of heterologous proteins |
JP5444553B2 (en) | 2007-04-27 | 2014-03-19 | フェネックス インコーポレイテッド | Methods for rapidly screening microbial hosts to identify specific strains with improved yield and / or quality of heterologous protein expression |
KR20110016430A (en) | 2007-07-03 | 2011-02-17 | 암젠 인코퍼레이티드 | Measurement of protein using inclusion body dry weight |
EP2188302B1 (en) | 2007-07-09 | 2017-11-01 | Genentech, Inc. | Prevention of disulfide bond reduction during recombinant production of polypeptides |
EP2185689A2 (en) | 2007-08-09 | 2010-05-19 | Genzyme Corporation | Method of treating autoimmune disease with mesenchymal stem cells |
US8758761B2 (en) * | 2007-09-30 | 2014-06-24 | University Of Florida Research Foundation, Inc. | Combination therapies for treating type 1 diabetes |
US8570393B2 (en) * | 2007-11-30 | 2013-10-29 | Cognex Corporation | System and method for processing image data relative to a focus of attention within the overall image |
EP2070950A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Hydroxyalkyl starch derivatives and process for their preparation |
EP2070951A1 (en) * | 2007-12-14 | 2009-06-17 | Fresenius Kabi Deutschland GmbH | Method for producing a hydroxyalkyl starch derivatives with two linkers |
NZ620606A (en) | 2008-02-08 | 2015-08-28 | Ambrx Inc | Modified leptin polypeptides and their uses |
EP2248832B1 (en) | 2008-02-18 | 2014-09-03 | Jiangsu Hengrui Medicine Co., Ltd. | A g-csf conjugate modified by water-soluble polymer |
JOP20190083A1 (en) | 2008-06-04 | 2017-06-16 | Amgen Inc | Fgf21 mutant fusion polypeptides and uses thereof |
WO2010011767A2 (en) | 2008-07-22 | 2010-01-28 | Duke Debra M | Compositions and methods for treating symptoms associated with menopause, hormonal variations and arthritis |
PE20110426A1 (en) | 2008-07-23 | 2011-07-01 | Ambrx Inc | MODIFIED BOVINE G-CSF POLYPEPTIDES |
US9151289B2 (en) | 2008-08-21 | 2015-10-06 | Cummins Inc. | Fuel pump |
CN102625811B (en) | 2008-10-10 | 2016-09-21 | 安姆根有限公司 | FGF21 mutant and application thereof |
RU2539832C2 (en) | 2008-10-17 | 2015-01-27 | Дана-Фарбер Кэнсер Инститьют, Инк. | Muc-1 protein cytoplasmic domain peptides as cancer inhibitors |
US9189670B2 (en) * | 2009-02-11 | 2015-11-17 | Cognex Corporation | System and method for capturing and detecting symbology features and parameters |
EP2427207B1 (en) | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
EA021425B1 (en) | 2009-05-05 | 2015-06-30 | Амген Инк. | Fgf21 mutants and uses thereof |
MX2011013903A (en) * | 2009-06-17 | 2012-05-08 | Amgen Inc | Chimeric fgf19 polypeptides and uses thereof. |
MX2012006397A (en) | 2009-12-02 | 2012-11-30 | Amgen Inc | Binding proteins that bind to human fgfr1c, human î²-klotho and both human fgfr1c and humanî²-klotho. |
UA109888C2 (en) | 2009-12-07 | 2015-10-26 | ANTIBODY OR ANTIBODILITY ANTIBODY OR ITS BINDING TO THE β-CLOTE, FGF RECEPTORS AND THEIR COMPLEXES | |
CA2784800A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified porcine somatotropin polypeptides and their uses |
CA2784793A1 (en) | 2009-12-21 | 2011-07-21 | Ambrx, Inc. | Modified bovine somatotropin polypeptides and their uses |
EP2548017A2 (en) | 2010-03-15 | 2013-01-23 | Genus Oncology, Llc | Small molecule inhibitors of muc1 and methods of identifying the same |
US20130130283A1 (en) | 2010-03-23 | 2013-05-23 | Imba - Institut Fur Molekulare Biotechnologie Gmbh | Methods for Identifying Inhibitors of the Type III Secretion System |
US9517264B2 (en) | 2010-04-15 | 2016-12-13 | Amgen Inc. | Human FGF receptor and β-Klotho binding proteins |
AR083006A1 (en) | 2010-09-23 | 2013-01-23 | Lilly Co Eli | FORMULATIONS FOR THE STIMULATING FACTOR OF COLONIES OF GRANULOCITS (G-CSF) BOVINE AND VARIANTS OF THE SAME |
CN103403019B (en) | 2010-09-28 | 2016-10-12 | 埃格里昂制药股份有限公司 | There is the engineered polypeptide of the acting duration of enhancing |
US8889630B2 (en) | 2011-12-23 | 2014-11-18 | Carlos Lopez | Method for hair regrowth using Granulocyte-Colony Stimulating Factor |
EP2897633B1 (en) | 2012-09-18 | 2020-01-01 | UTI Limited Partnership | Treatment of pain by inhibition of usp5 de-ubiquitinase |
WO2014151683A1 (en) | 2013-03-15 | 2014-09-25 | Bayer Healthcare Llc | Gla domains as targeting agents |
LT6161B (en) | 2013-09-27 | 2015-06-25 | Uab Profarma | Fused proteins of granulocyte colony-stimulating factor with other partners of growh factor, preferably with stem cell factor, and method of preparation thereof |
WO2015057724A1 (en) | 2013-10-14 | 2015-04-23 | Nora Therapeutics, Inc. | Use of g-csf for treating or preventing villitis of unknown etiology in a human female |
US20160361426A1 (en) * | 2015-06-11 | 2016-12-15 | Prolong Pharmaceuticals, LLC | Pegylated granulocyte colony stimulating factor (gcsf) |
WO2017067958A1 (en) * | 2015-10-19 | 2017-04-27 | Sandoz Ag | Improved coding sequence for human g-csf |
CN108384747A (en) * | 2018-03-05 | 2018-08-10 | 安徽省农业科学院园艺研究所 | Express the Chinese hamster ovary celI serum free suspension cultural method of Rabies virus antibody |
WO2021068074A1 (en) * | 2019-10-08 | 2021-04-15 | Zymeworks Inc. | Modified extracellular domain of granulocyte colony-stimulating factor receptor (g-csfr) and cytokines binding same |
AU2020406137A1 (en) | 2019-12-17 | 2022-06-16 | Eberhard Karls Universität Tübingen | Novel G-CSF mimics and their applications |
Family Cites Families (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
WO1985000817A1 (en) * | 1983-08-10 | 1985-02-28 | Amgen | Microbial expression of interleukin ii |
US4810643A (en) * | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS6263335A (en) * | 1985-09-13 | 1987-03-20 | Fuji Photo Film Co Ltd | Processing method for chemical reaction information |
US4908773A (en) * | 1987-04-06 | 1990-03-13 | Genex Corporation | Computer designed stabilized proteins and method for producing same |
DK203187A (en) * | 1986-04-22 | 1987-10-23 | Immunex Corp | HUMAN G-CSF PROTEIN EXPRESSION |
WO1988001297A1 (en) * | 1986-08-11 | 1988-02-25 | Cetus Corporation | Expression of g-csf and muteins thereof |
US4704692A (en) * | 1986-09-02 | 1987-11-03 | Ladner Robert C | Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides |
NO176799C (en) * | 1986-12-23 | 1995-05-31 | Kyowa Hakko Kogyo Kk | DNA encoding a polypeptide, recombinant plasmid that encodes and can express a polypeptide and method for producing this polypeptide |
US4853871A (en) * | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
GB2213821B (en) * | 1987-12-23 | 1992-01-02 | British Bio Technology | Synthetic human granulocyte colony stimulating factor gene |
US4904584A (en) * | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5153265A (en) * | 1988-01-20 | 1992-10-06 | Cetus Corporation | Conjugation of polymer to colony stimulating factor-1 |
CA1340810C (en) * | 1988-03-31 | 1999-11-02 | Motoo Yamasaki | Polypeptide derivatives of human granulocyte colony stimulating factor |
DE68918331T2 (en) * | 1988-06-03 | 1995-05-18 | Chugai Pharmaceutical Co Ltd | Human granulocyte crystalline colony stimulation factor and its production. |
US5025388A (en) * | 1988-08-26 | 1991-06-18 | Cramer Richard D Iii | Comparative molecular field analysis (CoMFA) |
US5218092A (en) | 1988-09-29 | 1993-06-08 | Kyowa Hakko Kogyo Co., Ltd. | Modified granulocyte-colony stimulating factor polypeptide with added carbohydrate chains |
US5166322A (en) * | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
US5109119A (en) * | 1989-06-06 | 1992-04-28 | Schering Corporation | Crystalline r-h-gm-csf and method |
US5265030A (en) * | 1990-04-24 | 1993-11-23 | Scripps Clinic And Research Foundation | System and method for determining three-dimensional structures of proteins |
GB9107846D0 (en) * | 1990-04-30 | 1991-05-29 | Ici Plc | Polypeptides |
DE4014750A1 (en) | 1990-05-08 | 1991-11-14 | Boehringer Mannheim Gmbh | MUTEINE OF THE GRANULOCYTE-STIMULATING FACTOR (G-CSF) |
JP3249147B2 (en) | 1990-06-01 | 2002-01-21 | キリン−アムジエン・インコーポレーテツド | Oral preparation containing bioactive protein |
IE912365A1 (en) | 1990-07-23 | 1992-01-29 | Zeneca Ltd | Continuous release pharmaceutical compositions |
DK0546124T4 (en) | 1990-08-29 | 2003-05-19 | Inst Genetics Llc | Multiple-domain hematopoiesis stimulators |
US5124297A (en) | 1990-12-07 | 1992-06-23 | Amoco Corporation | Olefin polymerization and copolymerization catalyst |
DE4105480A1 (en) | 1991-02-21 | 1992-08-27 | Boehringer Mannheim Gmbh | IMPROVED ACTIVATION OF RECOMBINANT PROTEINS |
JPH06506217A (en) * | 1991-03-18 | 1994-07-14 | エンゾン,インコーポレーテッド | Hydrazine-containing conjugates of polypeptides or glycopolypeptides and polymers |
US5157736A (en) * | 1991-04-19 | 1992-10-20 | International Business Machines Corporation | Apparatus and method for optical recognition of chemical graphics |
US5386507A (en) * | 1991-07-18 | 1995-01-31 | Teig; Steven L. | Computer graphics system for selectively modelling molecules and investigating the chemical and physical properties thereof |
ATE173763T1 (en) * | 1991-08-30 | 1998-12-15 | Hutchinson Fred Cancer Res | HYBRID CYTOKINE |
JP2638359B2 (en) * | 1991-11-26 | 1997-08-06 | 富士通株式会社 | Constraint condition generator for molecular dynamics method |
JPH08507916A (en) * | 1992-06-09 | 1996-08-27 | カイロン コーポレイション | Crystallization of M-CSF |
US6153183A (en) | 1992-11-24 | 2000-11-28 | G. D. Searle & Company | Co-administration of interleukin-3 mutant polypeptides with CSF's or cytokines for multi-lineage hematopoietic cell production |
US5772992A (en) | 1992-11-24 | 1998-06-30 | G.D. Searle & Co. | Compositions for co-administration of interleukin-3 mutants and other cytokines and hematopoietic factors |
US5738849A (en) | 1992-11-24 | 1998-04-14 | G. D. Searle & Co. | Interleukin-3 (IL-3) variant fusion proteins, their recombinant production, and therapeutic compositions comprising them |
US6057133A (en) | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
CA2150117A1 (en) | 1992-11-24 | 1994-06-09 | S. Christopher Bauer | Interleukin-3 (il-3) mutant polypeptides |
US5424963A (en) * | 1992-11-25 | 1995-06-13 | Photon Research Associates, Inc. | Molecular dynamics simulation method and apparatus |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5635599A (en) | 1994-04-08 | 1997-06-03 | The United States Of America As Represented By The Department Of Health And Human Services | Fusion proteins comprising circularly permuted ligands |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
EP0807181A1 (en) | 1995-02-03 | 1997-11-19 | G.D. Searle & Co. | NOVEL c-MPL LIGANDS |
US6017523A (en) | 1995-06-06 | 2000-01-25 | G.D. Searle & Co. | Therapeutic methods employing mutant human interleukin-3 (IL-3) polypeptides |
KR100456212B1 (en) | 1995-10-05 | 2005-01-15 | 지.디. 썰 엘엘씨 | Multi-functional hematopoietic receptor agonists |
EP0859843A1 (en) | 1995-10-05 | 1998-08-26 | G.D. Searle & Co. | Novel g-csf receptor agonists |
US6100070A (en) | 1995-10-05 | 2000-08-08 | G. D. Searle & Co. | G-CSF receptor agonists |
US6066318A (en) | 1995-10-05 | 2000-05-23 | G.D. Searle & Co. | Multi-functional hematopoietic fusion proteins between sequence rearranged C-MPL receptor agonists and other hematopoietic factors |
EP0870027A1 (en) | 1995-10-05 | 1998-10-14 | G.D. Searle & Co. | Novel c-mpl receptor agonists |
US5969105A (en) | 1996-10-25 | 1999-10-19 | Feng; Yiqing | Stem cell factor receptor agonists |
US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
EP0935663A2 (en) | 1996-10-25 | 1999-08-18 | G.D. SEARLE & CO. | Multi-functional chimeric hematopoietic receptor agonists |
CA2284127A1 (en) | 1997-04-11 | 1998-10-22 | G.D. Searle & Co. | Flt3 ligand chimeric proteins |
WO2000018905A1 (en) | 1998-09-25 | 2000-04-06 | G.D. Searle & Co. | Method of producing permuteins by scanning permutagenesis |
US6555660B2 (en) | 2000-01-10 | 2003-04-29 | Maxygen Holdings Ltd. | G-CSF conjugates |
ES2556338T3 (en) | 2001-10-10 | 2016-01-15 | Novo Nordisk A/S | Remodeling and glycoconjugation of peptides |
-
1993
- 1993-01-28 US US08/010,099 patent/US5581476A/en not_active Expired - Lifetime
-
1994
- 1994-01-25 CN CN94191031A patent/CN1118572C/en not_active Expired - Lifetime
- 1994-01-25 KR KR1019950703096A patent/KR100375274B1/en not_active IP Right Cessation
- 1994-01-25 NZ NZ314960A patent/NZ314960A/en not_active IP Right Cessation
- 1994-01-25 KR KR10-2001-7006530A patent/KR100390338B1/en not_active IP Right Cessation
- 1994-01-25 NZ NZ513422A patent/NZ513422A/en not_active IP Right Cessation
- 1994-01-25 AU AU60957/94A patent/AU697451B2/en not_active Expired
- 1994-01-25 JP JP6517294A patent/JPH08506018A/en not_active Withdrawn
- 1994-01-25 CA CA002239360A patent/CA2239360C/en not_active Expired - Lifetime
- 1994-01-25 WO PCT/US1994/000913 patent/WO1994017185A1/en active Application Filing
- 1994-01-25 NZ NZ261765A patent/NZ261765A/en not_active IP Right Cessation
- 1994-01-25 CN CN2006101014030A patent/CN1970571B/en not_active Expired - Lifetime
- 1994-01-25 NZ NZ332188A patent/NZ332188A/en not_active IP Right Cessation
- 1994-01-25 CA CA002153896A patent/CA2153896C/en not_active Expired - Lifetime
- 1994-01-25 CA CA2381489A patent/CA2381489C/en not_active Expired - Lifetime
- 1994-01-25 CN CN03145268XA patent/CN1495197B/en not_active Expired - Lifetime
- 1994-01-25 CA CA2711007A patent/CA2711007C/en not_active Expired - Lifetime
- 1994-01-26 IL IL145994A patent/IL145994A/en not_active IP Right Cessation
- 1994-01-26 IL IL10844694A patent/IL108446A/en not_active IP Right Cessation
- 1994-01-26 IL IL124112A patent/IL124112A/en not_active IP Right Cessation
- 1994-01-27 DK DK10011853.8T patent/DK2345724T3/en active
- 1994-01-27 DK DK04019074.6T patent/DK1482046T3/en active
- 1994-01-27 ES ES04019074T patent/ES2382927T3/en not_active Expired - Lifetime
- 1994-01-27 EP EP94101207A patent/EP0612846B1/en not_active Expired - Lifetime
- 1994-01-27 EP EP99112115A patent/EP0965638A3/en not_active Withdrawn
- 1994-01-27 PT PT04019074T patent/PT1482046E/en unknown
- 1994-01-27 DK DK94101207T patent/DK0612846T3/en active
- 1994-01-27 AT AT94101207T patent/ATE195552T1/en active
- 1994-01-27 EP EP99113571A patent/EP0974655A3/en not_active Withdrawn
- 1994-01-27 DE DE69425516T patent/DE69425516T2/en not_active Expired - Lifetime
- 1994-01-27 PT PT94101207T patent/PT612846E/en unknown
- 1994-01-27 EP EP98113221A patent/EP0890640A3/en not_active Withdrawn
- 1994-01-27 EP EP10011853.8A patent/EP2345724B1/en not_active Revoked
- 1994-01-27 PT PT100118538T patent/PT2345724E/en unknown
- 1994-01-27 EP EP01128744A patent/EP1233065A1/en not_active Withdrawn
- 1994-01-27 ES ES94101207T patent/ES2150951T3/en not_active Expired - Lifetime
- 1994-01-27 AT AT04019074T patent/ATE553199T1/en active
- 1994-01-27 EP EP04019073A patent/EP1482045A3/en not_active Withdrawn
- 1994-01-27 EP EP04019074A patent/EP1482046B1/en not_active Expired - Lifetime
- 1994-01-27 ZA ZA94568A patent/ZA94568B/en unknown
- 1994-01-27 ES ES10011853T patent/ES2422269T3/en not_active Expired - Lifetime
-
1995
- 1995-05-24 US US08/448,716 patent/US5790421A/en not_active Expired - Lifetime
- 1995-07-27 FI FI953593A patent/FI120769B/en not_active IP Right Cessation
- 1995-07-27 NO NO952974A patent/NO952974L/en not_active Application Discontinuation
-
1998
- 1998-04-15 IL IL12411198A patent/IL124111A/en not_active IP Right Cessation
- 1998-07-19 IL IL12539898A patent/IL125398A0/en not_active IP Right Cessation
- 1998-07-31 HK HK98109568A patent/HK1009288A1/en not_active IP Right Cessation
- 1998-08-28 AU AU81970/98A patent/AU8197098A/en not_active Abandoned
-
1999
- 1999-05-03 US US09/304,186 patent/US6261550B1/en not_active Expired - Lifetime
-
2000
- 2000-05-30 NZ NZ504840A patent/NZ504840A/en not_active IP Right Cessation
- 2000-11-02 GR GR20000402433T patent/GR3034745T3/en unknown
- 2000-11-23 LV LV000158A patent/LV12642B/en unknown
-
2001
- 2001-01-03 US US09/754,532 patent/US6632426B2/en not_active Expired - Fee Related
- 2001-10-17 IL IL14599401A patent/IL145994A0/en unknown
- 2001-12-20 US US10/032,108 patent/US7381804B2/en not_active Expired - Fee Related
-
2003
- 2003-04-02 NO NO20031497A patent/NO20031497L/en unknown
- 2003-09-25 JP JP2003333761A patent/JP2004113243A/en not_active Withdrawn
-
2005
- 2005-04-25 US US11/113,581 patent/US8058398B2/en not_active Expired - Fee Related
- 2005-11-17 JP JP2005333253A patent/JP2006096762A/en not_active Withdrawn
- 2005-11-17 JP JP2005333254A patent/JP2006137762A/en not_active Withdrawn
-
2007
- 2007-11-27 HK HK07112941.8A patent/HK1107356A1/en unknown
-
2008
- 2008-07-15 JP JP2008183538A patent/JP2009057368A/en not_active Withdrawn
-
2009
- 2009-10-21 FI FI20090384A patent/FI123078B/en not_active IP Right Cessation
- 2009-10-30 JP JP2009249964A patent/JP2010059170A/en active Pending
- 2009-12-08 NO NO20093489A patent/NO20093489L/en not_active Application Discontinuation
-
2011
- 2011-04-11 JP JP2011087129A patent/JP2011207885A/en not_active Withdrawn
-
2013
- 2013-08-12 LU LU92265C patent/LU92265I2/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2239360A1 (en) | G-csf analog compositions and methods | |
EP0183350A3 (en) | Dna endcoding human colony stimulating factor, peptide encoded thereby,vectors and transformed hosts containing such dna, and the production of all thereof | |
CA2294516A1 (en) | Ikk-.beta. proteins, nucleic acids and methods | |
CA2006473A1 (en) | Improved anti-infective therapy | |
AU7566587A (en) | Stable pharmacuetical preparation containing granulocyte colony stimulating factor and process for producing the same | |
AU631312B2 (en) | Muteins of the granulocyte colony stimulating factor (g-csf) | |
AU6312186A (en) | Pharmaceutical composition for the treatment of leukopenia | |
IL90334A0 (en) | Genetic transformation of b.thuringiensis,vectors used therefor,host cells transformed by the vectors and use of said cells as insecticides | |
CA2089111A1 (en) | Smooth muscle mitogen and isolated dna coding therefor | |
AU7726287A (en) | Process for the preparation of compounds comprising triazole or imidazole and tetrahydrofuran groups and new compounds used in the process | |
AU7516594A (en) | Pre-binding of retroviral vector particles with complement components to enable the performance of human gene therapy (in vivo) | |
IL81023A (en) | Human interferon-b2a, vectors containing genes coding for said interferon-b2a, cell lines producing same and pharmaceutical compositions containing it |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
MKEX | Expiry |
Effective date: 20140127 |